Details

Autor(en) / Beteiligte

• Grassi, G G
• Moore, EP
• White, LO
• Speller, DCE
• Finch, RG
• Wilkinson, PJ (eds)

Titel

Cefodizime in clinical use: A review of the clinical trial reports

Erscheinungsjahr

1990

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The clinical efficacy of cefodizime has been tested, above all in lower respiratory tract infections (LRTI) and uncomplicated urinary tract infections (UTI), performed in 151 centres in Europe, Latin America, South-Eastern Asia and South Africa. Of 3791 patients, 2260 could be evaluated for efficacy and safety. Comparative studies in LRTI were carried out vs cefotaxime and cefuroxime (301 vs 299 patients): both clinical and bacteriological results were superimposable (range of satisfactory clinical outcomes from 86% to 95%; bacteriological eradication 95% to 100%). In open studies (533 evaluable patients) the percentage of clinical successes ranged from 79 multiplied by 1% to 91 multiplied by 8% and the bacteriological eradication from about 87% to 90%, according to the type of infections. Side effects could be evaluated in 5801 patients, 3 multiplied by 79% of patients showed side effects (1 multiplied by 99% gastrointestinal disturbances, 0 multiplied by 9% rash or urticaria, 0 multiplied by 9% other effects); 1 multiplied by 13% of patients required discontinuation of treatment.